Trials / Terminated
TerminatedNCT02311088
Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor
Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor - A Double-blinded, Placebo-controlled, Randomized, Multicenter, Development Phase II Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Uppsala University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ticagrelor treatment is associated with increased rates of dyspnea, where previous studies have implied a possible role of adenosine. The purpose of this study is to determine if the caffeine-antagonist is effective in reducing dyspnea related to ticagrelor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Caffeine | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-12-01
- First posted
- 2014-12-08
- Last updated
- 2016-02-08
Locations
9 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02311088. Inclusion in this directory is not an endorsement.